Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Bristol-Myers Squibb Co., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data reflects notable fluctuations in key performance indicators over the five-year period under review. The analysis reveals oscillations in profitability, changes in capital structure, and varying efficiency in the use of invested capital.

Net Operating Profit After Taxes (NOPAT)
NOPAT shows significant volatility with large positive and negative values. Initially, there is a substantial negative figure, which is followed by a marked recovery in 2021. This positive momentum diminishes in 2022 but rebounds again in 2023. However, the most recent year reflects a sharp decline into a deeply negative result, signaling considerable operational challenges or extraordinary expenses that have adversely impacted after-tax operating profit.
Cost of Capital
The cost of capital exhibits a gradual upward trend from 7.23% to roughly 7.99%, indicating a moderate increase in the company’s expense of financing over the period. After peaking in 2022, it slightly declines and stabilizes around 7.5% through to 2024. This trend suggests a relatively stable but slightly elevated risk profile or changes in market conditions affecting capital cost.
Invested Capital
Invested capital demonstrates a consistent decline year over year, decreasing from over 90 billion to approximately 62.6 billion. This reduction suggests either divestments, asset disposal, or a strategic shift towards leaner capital deployment. The shrinking invested capital base could imply a focus on improving capital efficiency or responding to operational challenges.
Economic Profit
Economic profit mirrors the volatility observed in NOPAT but with sharper negative swings, especially in the initial and final years. After a very negative economic profit at the start, there is a small positive recovery in 2021 followed by a return to negative territory in 2022. The positive trend returns in 2023 but is again reversed drastically in 2024. These trends reflect inconsistent creation of shareholder value, with economic profit frequently falling below the cost of capital, indicating periods where the company destroyed value rather than generated it.

Overall, the data underscores a cycle of operational and financial instability, with intermittent improvements offset by steep declines. The company’s efforts to reduce invested capital have not consistently translated into sustained economic profitability. The fluctuations in profitability and economic profit, coupled with a relatively stable yet elevated cost of capital, highlight ongoing challenges in managing efficient growth and value creation.


Net Operating Profit after Taxes (NOPAT)

Bristol-Myers Squibb Co., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings (loss) attributable to BMS
Deferred income tax expense (benefit)1
Increase (decrease) in allowance for expected credit loss2
Increase (decrease) in restructuring liability3
Increase (decrease) in equity equivalents4
Interest expense
Interest expense, operating lease liability5
Adjusted interest expense
Tax benefit of interest expense6
Adjusted interest expense, after taxes7
(Gain) loss on marketable securities
Investment income, before taxes
Tax expense (benefit) of investment income8
Investment income, after taxes9
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowance for expected credit loss.

3 Addition of increase (decrease) in restructuring liability.

4 Addition of increase (decrease) in equity equivalents to net earnings (loss) attributable to BMS.

5 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

6 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

7 Addition of after taxes interest expense to net earnings (loss) attributable to BMS.

8 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

9 Elimination of after taxes investment income.


Net Earnings (Loss) Attributable to BMS
The net earnings exhibit significant volatility over the five-year period. In 2020, the company experienced a substantial loss of approximately $9.015 billion. This was followed by a strong recovery in 2021, with net earnings turning positive at around $6.994 billion. The positive trend continued through 2022 and 2023, with earnings of $6.327 billion and $8.025 billion, respectively, indicating operational improvements and profitability restoration. However, in 2024, the net earnings again declined sharply to a loss of about $8.948 billion, suggesting potential one-time charges, operational challenges, or market conditions adversely affecting profitability.
Net Operating Profit After Taxes (NOPAT)
The NOPAT values reflect a similar pattern of volatility as net earnings. In 2020, the company reported a significant negative NOPAT of approximately $6.822 billion. The following year showed a substantial positive turnaround with NOPAT reaching $6.656 billion. Despite this improvement, the subsequent years showed a decline in NOPAT, falling to $4.571 billion in 2022 and recovering slightly to $5.869 billion in 2023. In 2024, there was a notable decline to a negative $9.292 billion, aligning with the net earnings loss. This suggests that operational efficiency and tax impacts fluctuated considerably, with a sharp deterioration in 2024 likely driven by operational issues or exceptional expenses.
Overall Trend and Insights
Both net earnings and NOPAT demonstrate a pronounced cyclical pattern, with strong losses in 2020 followed by recovery in the subsequent years up to 2023, and then a substantial reversal back to losses in 2024. This pattern indicates that while the company was able to restore profitability after a difficult 2020, it encountered renewed challenges in 2024. The divergence between earnings and operating profit in some years suggests that non-operating factors, such as extraordinary items or tax effects, may have influenced net profitability. The data points to the necessity for a deeper review of underlying causes behind the 2024 downturn, including potential one-time charges, market dynamics, or changes in operational efficiency.

Cash Operating Taxes

Bristol-Myers Squibb Co., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Tax Provision
The income tax provision shows a fluctuating trend over the five-year period. Starting at 2,124 million US dollars in 2020, it declined significantly to 1,084 million in 2021, followed by a moderate increase to 1,368 million in 2022. In the subsequent years, the provision dropped sharply to 400 million in 2023 but experienced a slight rebound to 554 million in 2024. This pattern suggests variability in taxable income or changes in tax strategy or regulations impacting the provision calculation.
Cash Operating Taxes
Cash operating taxes display a different trajectory compared to income tax provisions, indicating potential timing differences or other tax-related factors. The amount nearly doubled from 1,445 million in 2020 to 2,764 million in 2021, followed by a further substantial increase to 4,376 million in 2022. However, in 2023, cash operating taxes declined to 3,947 million and continued to drop to 3,068 million in 2024. Despite the reductions in recent years, cash tax payments remain significantly higher than in 2020. This trend may reflect changes in cash flow management, tax payment scheduling, or adjustments related to tax liabilities and credits.
Overall Insights
The divergence between income tax provision and cash operating taxes is notable. While income tax provisions generally decreased over the period with some volatility, cash operating taxes rose sharply before declining in the last two years but still remained elevated relative to 2020. These contrasting patterns could indicate differences in accounting recognition of tax expenses versus actual cash outflows. The fluctuations in both indicators highlight the importance of analyzing tax-related cash impacts separately from accounting provisions to fully understand the company's tax position and its effect on liquidity and profitability.

Invested Capital

Bristol-Myers Squibb Co., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term debt obligations
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Total BMS shareholders’ equity
Net deferred tax (assets) liabilities2
Allowance for expected credit loss3
Restructuring liability4
Equity equivalents5
Accumulated other comprehensive (income) loss, net of tax6
Noncontrolling interest
Adjusted total BMS shareholders’ equity
Construction in progress7
Marketable debt securities and equity investments8
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of restructuring liability.

5 Addition of equity equivalents to total BMS shareholders’ equity.

6 Removal of accumulated other comprehensive income.

7 Subtraction of construction in progress.

8 Subtraction of marketable debt securities and equity investments.


Total reported debt & leases
There is a noticeable reduction in total reported debt and leases from 2020 to 2022, falling from approximately $51.7 billion to about $40.7 billion. However, the debt level stabilizes around $41.5 billion in 2023 before increasing significantly to $51.2 billion in 2024, approaching the 2020 debt level once again.
Total BMS shareholders’ equity
The shareholders’ equity shows a consistent declining trend over the five-year period. Starting at around $37.8 billion in 2020, it decreases gradually each year, falling to roughly $16.3 billion in 2024. This decline is particularly pronounced between 2023 and 2024, where equity drops by nearly 45%, indicating potential challenges impacting the company’s net worth.
Invested capital
Invested capital follows a downward trend over the period, beginning at approximately $90.1 billion in 2020 and decreasing steadily every year to around $62.7 billion in 2024. The continuous reduction suggests contraction in the company's asset base or potential divestitures and may relate to the simultaneously falling equity and fluctuating debt levels.

Cost of Capital

Bristol-Myers Squibb Co., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Bristol-Myers Squibb Co., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit exhibits significant volatility over the five-year period. Starting from a substantial negative value in 2020, it shifts to a positive figure in 2021, followed by a decline into negative territory again in 2022. There is a noticeable recovery in 2023 with a positive economic profit, but the value sharply deteriorates to a large negative figure by 2024. This pattern suggests intermittent periods of value creation interspersed with substantial value destruction.
Invested Capital
Invested capital shows a consistent decreasing trend year-over-year from 2020 through 2024. The capital base contracts significantly from approximately 90 billion US dollars in 2020 to around 62.7 billion US dollars in 2024, indicating a reduction in the company's asset investment or resources employed in operations.
Economic Spread Ratio
The economic spread ratio reveals considerable fluctuations, moving from a negative rate of nearly -15% in 2020 to a marginally positive value in 2021. It declines again into negative in 2022, rises slightly positive in 2023, then plunges sharply to -22.37% in 2024. This measure indicates the company's returns relative to its cost of capital, with frequent performance inconsistencies and a notably poor return in the final year examined.
Summary
Overall, the data indicate a shrinking capital base aligned with unstable profitability and return measures. Such variability in economic profit and spread ratio suggests challenges in consistently generating returns above the cost of capital. The steep decline in 2024 across both profit and spread metrics, alongside continued contraction in invested capital, may signal operational difficulties or strategic shifts impacting value generation. These trends warrant closer scrutiny to identify underlying causes and assess future financial sustainability.

Economic Profit Margin

Bristol-Myers Squibb Co., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Revenues
Revenues showed fluctuations over the observed period, increasing from approximately 42.5 billion USD in 2020 to about 46.4 billion USD in 2021. This was followed by a slight decline to around 46.2 billion USD in 2022 and a further decrease to 45 billion USD in 2023. Notably, revenues rebounded significantly in 2024, reaching approximately 48.3 billion USD, the highest in the five-year span.
Economic Profit
The economic profit exhibited significant volatility and predominantly negative values. In 2020, the economic profit was deeply negative at around -13.3 billion USD. This showed a remarkable improvement in 2021, turning positive to approximately 569 million USD. However, the positive trend was not sustained, as economic profit dropped back into negative territory in 2022 and 2024, with values of roughly -1.2 billion USD and -14 billion USD, respectively. 2023 was a positive outlier again, with an economic profit near 800 million USD.
Economic Profit Margin
The economic profit margin followed a pattern similar to the economic profit. It was strongly negative in 2020 at -31.38%, improved to a slight positive margin of 1.23% in 2021, then declined to -2.51% in 2022. In 2023, it rose marginally to 1.78%, only to fall back sharply to -29.02% in 2024. This indicates large fluctuations in profitability efficiency relative to revenues, with only brief periods of marginal positive returns.
Overall Analysis
The data reveals a pattern of unstable profitability despite relatively steady revenue levels. Revenues, while fluctuating modestly, generally trended upward by the final year. Conversely, economic profit and its margin oscillated dramatically between negative and small positive values, indicating challenges in translating revenue into sustainable profit. The sharp declines in economic profit and margin in 2024 are notable, suggesting increased costs, diminished operational efficiency, or other financial pressures that offset the revenue growth. The alternating positive and negative economic profit points to episodic success in cost management or investment returns, but without a sustained upward trend in overall profitability.